Article
Clinical Evidence on the Magnitude of Change in Growth Pathway Activity in Relation to Tamoxifen Resistance is Required.
Current cancer drug targets - 1 Jan 2018
Mansouri Sepideh, Farahmand Leila, Teymourzadeh Azin, Majidzadeh-A Keivan
Abstract excerpt
BACKGROUND: Despite prolonged disease-free survival and overall survival rates in Estrogen Receptor (ER)-positive patients undergoing adjuvant treatment, Tamoxifen therapy tends to fail due to eventual acquisition of resistance. OBJECTIVE: Although numerous studies have emphasized the Role of Receptor Tyrosine Kinases (RTKs) in the development of Tamoxifen resistance, inadequate clinical evidence is available...
Topics
Join the communities discussing this publication.